RB1 and neoplasm: For example, nanomedicines can deliver Cyclin-Dependent Kinase (CDK) inhibitors to block RB phosphorylation (el-Deiry et al., 1993), thereby restoring its inhibition of E2F transcription factors and preventing excessive tumor cell proliferation.